NOT-CA-25-118: Notice of National Cancer Institutes Participation in PA-25-304, NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Required) and in PA-25-306 (Parent R21 Clinical Trial Required)

Notice of National Cancer Institute’s Participation in PA-25-304, NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Required) and in PA-25-306 (Parent R21 Clinical Trial Required)

Notice Number:

NOT-CA-25-118

Key Dates

Release Date:

September 2, 2025

Related Announcements

December 18, 2024 - NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed). See NOFO PA-25-304.
December 18, 2024 - NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required). See NOFO PA-25-306.

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) will participate in PA-25-304 "NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)" and PA-25-306 “NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)” effective for the October 16, 2025 due date and subsequent due dates.

The following text has been added to reflect NCI's participation in PA-25-304 & PA-25-306:

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

Assistance Listing Number(s)

93.393, 93.394, 93.395, 93.396, 93.399

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Applications Related to Cancer Treatment/Diagnosis (Preclinical Studies):
Morgan O'Hayre, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7482
Email: [email protected]

Applications Related to Cancer Treatment/Diagnosis (Clinical Studies):
Minkyung Song, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6139
Email: [email protected]

Applications Related to Cancer Prevention/Symptom Management:
Marjorie Perloff, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-7097
Email: [email protected]

Applications Related to Differences in Cancer Incidence and Outcomes:
Tiffany Wallace, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5114
Email: [email protected]

Applications related to Cancer Control:
Mukesh Verma, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6889
Email: [email protected]

Applications Related to the following Cancer Biology research areas:

Technology development or computational approaches:
Eric Johnson Chavarria, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7416
Email: [email protected]

Mechanisms and processes of metastasis and systemic effects of cancer:
Grace Ault, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6201
Email: [email protected]

Genetic and epigenetic mechanisms of tumorigenesis and mechanisms of chemical and physical carcinogenesis:
Keren Witkin, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6230
Email: [email protected]

Mechanisms of precancer states, oncogenic transformation, and tumor growth and behavior:
Stefan Maas, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-413-6230
Email: [email protected]

Mechanisms of early lesion- and primary tumor-microenvironment dynamics:
Elizabeth Woodhouse, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6205
Email: [email protected]

Cancer immunology, hematologic malignancies, or the role of microbial agents in cancer pathogenesis:
Lillian Kuo, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7867
Email: [email protected]

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]

Inquiries

Please direct all inquiries to:

Morgan O'Hayre, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7482
Email: [email protected]